Anixa Biosciences, Inc. earnings per share and revenue
On Jan 12, 2026, ANIX reported earnings of -0.09 USD per share (EPS) for Q4 25, missing the estimate of -0.08 USD, resulting in a -0.78% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.17% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.09 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Anixa Biosciences, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Anixa Biosciences, Inc. reported EPS of -$0.09, missing estimates by -0.78%, and revenue of $0.00, 0% as expectations.
How did the market react to Anixa Biosciences, Inc.'s Q4 2025 earnings?
The stock price moved down -1.17%, changed from $3.42 before the earnings release to $3.38 the day after.
When is Anixa Biosciences, Inc. expected to report next?
The next earning report is scheduled for Mar 09, 2026.
What are the forecasts for Anixa Biosciences, Inc.'s next earnings report?
Based on 5
analysts, Anixa Biosciences, Inc. is expected to report EPS of -$0.09 and revenue of -- for Q1 2026.